Celularity Announces Promising Phase 2 Results for Diabetic Foot Ulcer Treatment
A New Hope for Patients with Diabetic Foot Ulcers and Peripheral Artery Disease Do you or someone you know struggle with the healing of diabetic foot ulcers? The presence of peripheral artery disease (PAD) can make this condition even more challenging to treat. Celularity Inc. has announced encouraging results from a Phase 2 clinical trial […]
Celularity and BlueSphere Bio Collaborate on Cell Therapy Manufacturing
Celularity Inc., a cellular medicine company, has entered into a collaboration agreement with BlueSphere Bio (BSB).? Celularity will leverage its manufacturing capabilities to produce BSB’s T cell receptor (TCR) T cell therapies.? This partnership will focus on manufacturing and quality control at Celularity’s New Jersey facility for BSB’s therapies, including a treatment for Acute Myelogenous […]
Celularity Revolutionizing Cancer Treatment: The Breakthrough of Stem Cell Therapy
A New Era in Oncology In an exciting development for the field of oncology, Celularity Inc., a leading biotechnology company, is set to present compelling in vivo data at the AACR Annual Meeting 2024. This data showcases the significant impact of their groundbreaking stem cell therapy, PT-CD16, in reducing cancer tumors. Derived from human placental […]
Revolutionary Placental Biomaterials Transform Cell Therapy
Celularity Inc., a biotechnology company specializing in placental-derived allogeneic cell therapies and biomaterial products, has announced that it will present data on its proprietary extracellular matrices (ECM) at the International Conference on Biomaterials Science and Tissue Engineering (ICBSTE), taking place from July 24-26 in Osaka, Japan. The data includes benchtop and clinical case studies for […]